1. Home
  2. Labeler Index
  3. Eugia Us Llc
  4. 55150-177
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Levetiracetam NDC 55150-177 by Eugia Us Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

The text shows the results of a study in which the drug Levetiracetam was tested at two different doses (1000 mg/day and 3000 mg/day) compared to a placebo group (N=95). The percentages indicate the proportion of participants who benefited from the treatment, with the highest percentage being 39.6% for one of the Levetiracetam groups. The asterisk denotes that the Levetiracetam groups had statistically significant results compared to the placebo group.*

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

This is a statistical data table showing the percentage of effectiveness of Levetiracetam medication in treating an unknown condition. There were two doses of Levetiracetam given (1000 mg/day and 2000 mg/day) and a group of subjects were given a placebo for comparison. The data suggests that both doses of the medication were statistically significant in their effectiveness compared to the placebo group.*

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

This text represents the percentage results of a study comparing the effects of a placebo and a drug called Levetiracetam, which was taken at a dose of 3000 mg/day. The percentages, which are likely representing the proportion of patients who experienced a certain outcome, are 39.4%, 14.4%, 10%, and 0% respectively. The symbol "¥" likely represents the currency used in the study's country or currency conversion rate. The text also notes that the results for Levetiracetam were statistically significant when compared to the placebo group.*

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

The given text provides statistical information for a medical study that involved a "Placebo" group and another group treated with "Levetiracetam". The percentage values represent some kind of quantitative data obtained from the study, but without further context, it's hard to determine what they represent. However, the asterisk symbol indicates that the Levetiracetam treatment showed a statistically significant difference compared to the Placebo group.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

The text describes the results of a study comparing the effectiveness of a drug called Levetiracetam versus a placebo. The study involved 58 participants taking Levetiracetam and 51 participants taking a placebo. The numbers 19.6%, 10%, and 0% likely refer to the percentage of participants who experienced a certain outcome, but the specific outcome is not provided. The statement "*statistically significant versus placebo" indicates that the results for the Levetiracetam group were significantly different from those of the placebo group.*

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

This appears to be a table showing the percentage effectiveness of a drug called Levetiracetam compared to a placebo. There are two groups - one with 84 patients on placebo and one with 79 patients on Levetiracetam. The effectiveness of the drug is statistically significant when compared to the placebo.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg per 5 mL - Container Label - levetiracetam fig7

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg per 5 mL - Container Label - levetiracetam fig7

This is a description of a medication called "Ty Vi" from AuroMedis Pharma LLC, and is stored in a single dose vial. The medication is administered via injection and must be diluted prior to administration. The recommended dosage and storage information can be found in the package insert. The NDC (National Drug Code) is 55150-177-05 and it's only intended for intravenous use.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg per 5 mL - Container-Carton (10 Vial) - levetiracetam fig8

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg per 5 mL - Container-Carton (10 Vial) - levetiracetam fig8

Not available.*

Levetiracetam Chemical Structure - levetiracetam str

Levetiracetam Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.